Added to YB: 2024-06-05
Pitch date: 2024-04-17
VKTX [bullish]
Viking Therapeutics, Inc.
-45.33%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$4.4B
Pitch Price
$66.13
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.51
P/E
-18.45
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
Carillon Eagle Small Cap Growth Fund Portfolio Holding: Viking Therapeutics, Inc.
VKTX: Biotech obesity & NASH play. Lead injectable showed strong weight loss vs top drug tirzepatide. Oral version also potent in 4wk study. Investors excited by large potential GLP-1 market & impressive results from small indep lab. Meaningful breakthrough.
Read full article (1 min)